JP4968511B2 - Method for producing insulin-like growth factor-1 (IGF-1) in vivo - Google Patents
Method for producing insulin-like growth factor-1 (IGF-1) in vivo Download PDFInfo
- Publication number
- JP4968511B2 JP4968511B2 JP2006223710A JP2006223710A JP4968511B2 JP 4968511 B2 JP4968511 B2 JP 4968511B2 JP 2006223710 A JP2006223710 A JP 2006223710A JP 2006223710 A JP2006223710 A JP 2006223710A JP 4968511 B2 JP4968511 B2 JP 4968511B2
- Authority
- JP
- Japan
- Prior art keywords
- gas
- growth factor
- insulin
- microbubbles
- igf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title claims description 42
- 102100037852 Insulin-like growth factor I Human genes 0.000 title claims description 42
- 238000001727 in vivo Methods 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims 1
- 239000007789 gas Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000001953 sensory effect Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 102000018997 Growth Hormone Human genes 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- 230000013632 homeostatic process Effects 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 4
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/14—Measures for saving energy, e.g. in green houses
Landscapes
- Farming Of Fish And Shellfish (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、機能性マイクロバブル又は機能性マイクロバブル水の提供に関し、特に生物の体内においてインスリン様成長因子−１（ＩＧＦ−１）又は成長ホルモンを生成させる機能性マイクロバブル及び機能性マイクロバブル水の提供に関する。 TECHNICAL FIELD The present invention relates to provision of functional microbubbles or functional microbubble water, and in particular, functional microbubbles and functional microbubble water that produce insulin-like growth factor-1 (IGF-1) or growth hormone in the body of an organism. Related to the provision of.
昨今、微細気泡の製造技術及びその利用技術の開発が盛んに行われるようになってきて、重要な産業技術分野を形成するに至っている。
直径が数１０μｍ以下、特に５０μm以下の微細な気泡はマイクロバブルといわれ、その作用メカニズム、物理化学的性質、機能等は、未だ十分に解明されていない。
本発明者は、水産養殖及びバイオリアクターに適用可能なガス気泡供給器の開発に取組み、気泡の微細化を追求する過程において、種々の微細気泡発生装置を開発してきた。また、開発した発生装置を池や湖沼等の閉鎖水域の水質改善に用いるため、実証実験を重ね、種々の成果を得てきた。
Fine bubbles having a diameter of several tens of μm or less, particularly 50 μm or less are called microbubbles, and their action mechanism, physicochemical properties, functions, and the like have not been fully elucidated.
The present inventor has been working on the development of a gas bubble supply device applicable to aquaculture and bioreactors, and has developed various fine bubble generating devices in the process of pursuing finer bubbles. In addition, in order to use the developed generator to improve the water quality in closed water areas such as ponds and lakes, we have carried out demonstration experiments and obtained various results.
一方、インスリン様成長因子−１（ＩＧＦ−１）は、疾病予防とアンチエイジングに関わる重要な物質であって、分子量が7500のペプチドで、細胞のアポトーシスを抑制し、細胞の生存、増殖、そして分化に不可欠な重要な物質であることが知られている。
すなわち、インスリン様成長因子−１は、成長ホルモンの末梢での作用発現物質で、筋肉細胞、神経細胞などの細胞の増殖分化に重要な役割を演じるものであり、成長ホルモン欠損症で認められる多くの症候は、インスリン様成長因子−１の産生低下に起因すると考えられ、この病態の観察と成長ホルモン補充による効果の観察から、インスリン様成長因子−１の多彩で重要な作用が判明した。
In other words, insulin-like growth factor-1 is a substance that exhibits the action of growth hormone in the periphery, plays an important role in the proliferation and differentiation of cells such as muscle cells and nerve cells, and is often observed in growth hormone deficiency. These symptoms are considered to be caused by a decrease in the production of insulin-like growth factor-1. From the observation of this disease state and the effect of growth hormone supplementation, various and important actions of insulin-like growth factor-1 were revealed.
従来の研究結果から、マイクロバブル（ＭＢ）の生物作用として、牡蠣やホタテの成長促進作用が認められているが、マイクロバブルを利用して他の有用生物の育生を促進したり、疾病を治癒したりする発明、及びその開発やメカニズムの解明は殆どなされていなかった。
よって本発明は、マイクロバブルを利用して生物の育生を促進したり、疾病の治癒を図るなどの発明技術を提供しようとするものである。
According to the results of previous research, the growth of oysters and scallops has been recognized as a biological action of microbubbles (MB). However, microbubbles can be used to promote the growth of other useful organisms and to cure diseases. However, little has been done to elucidate the invention, its development and mechanism.
Therefore, the present invention intends to provide invention techniques such as promoting the growth of organisms using microbubbles, and curing diseases.
本発明者は、鋭意研究の結果、マイクロバブル又はマイクロバブル含有水を生物に供給すると、細胞の生存、増殖、そして分化に不可欠な重要な物質生物であるインスリン様成長因子−１（ＩＧＦ−１）の生成を促進することを見いだした。
本願発明は、該発見に基づいてなされたもので下記構成の生体（ただしヒトを除く。）内にインスリン様成長因子−１（ＩＧＦ−１）を生成させる方法に係るものである。
As a result of diligent research, the present inventor has provided insulin-like growth factor-1 (IGF-1) which is an important substance organism essential for cell survival, proliferation and differentiation when microbubbles or water containing microbubbles is supplied to an organism. ) Was found to promote the generation of
The present invention has been made on the basis of the discovery and relates to a method for producing insulin-like growth factor-1 (IGF-1) in a living body (except human) having the following constitution.
［１］ 気体と液体との混合液よりなる気液二相流体を、内側形状が円筒形又は円錐形の容器内で毎分２０，０００〜４０，０００回転（毎秒約３３０〜６７０回転）させて、同容器の中心部に液体及び気体の２相旋回流を形成させ、その２相旋回流の回転軸に沿って気体の負圧空洞部を形成させて、旋回気体空洞部を形成させ、その旋回によって気体を千切り、かつ粉砕して製造される、発生時に直径が１０〜４０μｍで、電位が−４０〜−１００ｍＶの微細気泡を含む機能性マイクロバブル水中に、生体（ただしヒトを除く。）を浸漬することにより生体内にインスリン様成長因子−１（ＩＧＦ−１）を生成させる方法。
[1] A gas-liquid two-phase fluid composed of a mixture of gas and liquid is rotated 20,000 to 40,000 revolutions per minute (about 330 to 670 revolutions per second) in a cylindrical or conical container. Forming a two-phase swirling flow of liquid and gas at the center of the container, forming a negative gas pressure cavity along the rotation axis of the two-phase swirling flow, and forming a swirling gas cavity, A living body (except for humans) is produced in functional microbubble water containing fine bubbles having a diameter of 10 to 40 μm and an electric potential of −40 to −100 mV . how to made insulin-like growth factor -1 (IGF-1) raw in vivo by) immersing the.
本願発明の機能性マイクロバブル又は機能性マイクロバブル水を、単に生物に供与するだけで、生物の血管内、臓器内あるいは皮膚内等の生物の体内にインスリン様成長因子−１（ＩＧＦ−１）含有濃度を上昇させることができ、特に肝臓や血漿（血液）中のインスリン様成長因子−１を飛躍的に上昇させることができる。
その結果、生物の育生促進や疾病の予防・治癒を図ることができる。
By simply supplying the functional microbubbles or functional microbubble water of the present invention to a living organism, insulin-like growth factor-1 (IGF-1) is introduced into the living organism such as blood vessels, organs or skin of the organism. The content concentration can be increased, and in particular, insulin-like growth factor-1 in the liver and plasma (blood) can be dramatically increased.
As a result, it is possible to promote the growth of organisms and to prevent or cure diseases.
本発明に係るマイクロバブル、マイクロバブル水及びインスリン様成長因子−１（ＩＧＦ−１）について、説明する。
「マイクロバブル、マイクロバブル水について」
本願発明に係るマイクロバブル（機能性マイクロバブル）は、気体と液体との混合液よりなる気液二相流体を、内側形状が円筒形又は円錐形の容器内で毎分２０，０００〜４０，０００回転あるいは毎秒約３００〜７００回転させて、同容器の中心部に液体及び気体の２相旋回流を形成させ、その２相旋回流の回転軸に沿って気体の負圧空洞部を形成させて、旋回気体空洞部を形成させ、その旋回によって気体を千切り、かつ粉砕して製造され、発生時に直径が１０〜４０μmで、電位が−４０〜−１００ｍＶの微細気泡となっているものである。
そして、発生後は所定の寿命を持って徐々に微細化し、消滅し溶解するものせる。
ここで、所定の寿命とは、大気圧が作用する水面近くの常圧の場合は数秒前後であり、高圧になるに従いその寿命がより長くなる。
すなわち、高圧下において発生時に好ましくは３０μｍ以下の気泡径を有し、発生後は前記微細気泡に比べ、より長い寿命を持って徐々に微細化し、水中での上昇過程において消滅・溶解する微細気泡で、高圧下とは１気圧以上の深い水面下をいう。
本願発明のマイクロバブルは、その発生時の大きさにおいて略５μｍ〜略４０μｍの直径のものである。
このようなマイクロバブルの物理的特性として、発生時に直径が１０〜４０μmで、電位が−４０〜−１００ｍＶの微細気泡で、その後、気泡径が小さくなるに従い、その電位量の絶対値は逆比例して増加するものである。
また、数百ミクロン〜数ミリメートル、あるいはそれ以上の気泡径の気泡（以下、通常気泡という）と比較して、表面張力が極端に大きく、内圧が高い。マイクロバブルが消滅する際の内圧は、数千気圧にも達するといわれている。
また、そのマイクロバブルの消滅・溶解時には、暗闇で自発光が確認できる程の高エネルギーを有するものであり、これを観測している。
The microbubble, microbubble water and insulin-like growth factor-1 (IGF-1) according to the present invention will be described.
"About microbubbles and microbubble water"
The microbubble according to the present invention (functional microbubble) is a gas-liquid two-phase fluid composed of a mixture of gas and liquid, and has an inner shape of 20,000 to 40,000 per minute in a cylindrical or conical container. 000 revolutions or about 300 to 700 revolutions per second to form a two-phase swirling flow of liquid and gas at the center of the container, and form a gas negative pressure cavity along the rotation axis of the two-phase swirling flow The swirling gas cavity is formed, and the swirling gas is shredded and pulverized to produce fine bubbles having a diameter of 10 to 40 μm and a potential of −40 to −100 mV when generated. .
And after generation | occurrence | production, it refines | miniaturizes gradually with a predetermined lifetime, and it will lose | dissolve and melt | dissolve.
Here, the predetermined life is around several seconds in the case of normal pressure near the water surface where atmospheric pressure acts, and the life becomes longer as the pressure increases.
That is, a fine bubble that has a bubble diameter of preferably 30 μm or less when generated under high pressure, gradually becomes finer with a longer life after the occurrence, and disappears / dissolves in the rising process in water. And under high pressure means deep below the water surface of 1 atmosphere or more.
The microbubbles of the present invention are those having a diameter of about 5 μm to about 40 μm at the time of generation.
As the physical characteristics of such microbubbles, the absolute value of the potential amount is inversely proportional to the microbubbles with a diameter of 10 to 40 μm and a potential of −40 to −100 mV when they are generated. And increase.
In addition, the surface tension is extremely large and the internal pressure is high as compared with bubbles having a bubble diameter of several hundred microns to several millimeters or more (hereinafter referred to as normal bubbles). The internal pressure when the microbubbles disappear is said to reach several thousand atmospheres.
In addition, when the microbubbles disappear and dissolve, they have such high energy that self-luminescence can be confirmed in the dark, and this is observed.
上述のようなマイクロバブルは、発生後比較的短時間で微細化し、消滅・溶解する過程において、強大な熱及び光のエネルギーを放出する。そのエネルギーの供給によって、生物の生理活性を促進させ、特に生体の血流促進を実現し、新陳代謝を高める気泡である。すなわち、マイクロバブルの発するエネルギーによって、生理活性を制御する物質が生体内に生成され、その結果として生理活性が促進されるものと推測される。
また、生理活性の結果として、生物本来の成長促進補助を大幅に可能とする。
そして、本願発明のマイクロバブルは、低温水中に身体又は身体の一部を浸した場合に、血流促進を図ることができる気泡でもある。ここで低温水とは、略３７度Ｃ〜略４０度Ｃ程度の温水を意味するが、本願発明に係るマイクロバブルの血流促進の作用により、より高温での入浴と同等の血流促進効果を得ることができる。また、身体の一部、例えば足及び脛に前記マイクロバブルを当てても血流促進を図ることができる。
さらに、溶存酸素濃度を高めることによる生理活性機能と、上述のように気泡自体による生理活性機能を共に備えている。
本願発明のマイクロバブルの発生過程においては、円筒状のスペースを構成する円周の接線方向に向けて液体を圧送することにより、円筒状スペースの軸線に沿って旋回流を生成させ、その旋回流の中心軸付近に負圧領域を形成させ、その負圧領域の一端から外部の気体が吸込まれ、その気体が前記負圧領域の他端に向って通過することによって、細かい紐状の旋回気体空洞部を形成させ、その旋回気体空洞部が前記圧送液により、縮径されて先細りとなり、千切られ、かつ、静液体に臨むことにより生成される。
The microbubbles as described above release powerful heat and light energy in the process of becoming finer and disappearing / dissolving in a relatively short time after generation. The supply of energy promotes the biological activity of the organism, in particular, promotes blood flow in the living body, and is a bubble that enhances metabolism. That is, it is presumed that a substance that controls physiological activity is generated in the living body by the energy generated by the microbubbles, and as a result, the physiological activity is promoted.
In addition, as a result of physiological activity, the growth promotion assistance inherent in living organisms can be greatly made possible.
And the microbubble of this invention is a bubble which can aim at blood-flow promotion, when a body or a part of body is immersed in low-temperature water. Here, the low-temperature water means hot water of about 37 ° C. to about 40 ° C. However, the blood flow promoting effect equivalent to that of bathing at a higher temperature due to the blood flow promoting action of the microbubbles according to the present invention. Can be obtained. In addition, blood flow can be promoted even if the microbubbles are applied to a part of the body, for example, a foot and a shin.
Furthermore, it has both the physiologically active function by increasing the dissolved oxygen concentration and the physiologically active function by the bubbles themselves as described above.
In the microbubble generation process of the present invention, a swirl flow is generated along the axis of the cylindrical space by pumping liquid toward the tangential direction of the circumference constituting the cylindrical space, and the swirl flow A negative pressure region is formed in the vicinity of the central axis of the gas, an external gas is sucked from one end of the negative pressure region, and the gas passes toward the other end of the negative pressure region, whereby a fine string-like swirling gas A hollow portion is formed, and the swirling gas hollow portion is reduced in diameter by the pressure-feeding liquid, becomes tapered, is chopped, and is generated by facing a static liquid.
次に、本願発明に係るマイクロバブルの気泡径は、均一であり、気泡同士の合体や分裂が起こり難く、極めて優れた分散性を示す。これに対して、通常気泡は、酸素吸収効率が悪く、また生理活性を起こさせることができない。
マイクロバブルが発生及びはじける際に生成される音エネルギーが、約キロヘルツ〜数１０キロヘルツ程度の振動で伝達される。
マイクロバブルは水中に長時間滞留する。マイクロバブルは、比較的短時間で消滅するが、同時にマイクロバブル発生装置からは大量のマイクロバブルが連続的に発生し続けることから、マイクロバブル全体として滞留する性質を備えている。
Next, the bubble diameters of the microbubbles according to the present invention are uniform, and coalescence and splitting of the bubbles hardly occur, and extremely excellent dispersibility is exhibited. In contrast, normal bubbles have poor oxygen absorption efficiency and cannot cause physiological activity.
The sound energy generated when the microbubbles are generated and popped is transmitted by vibrations of about kilohertz to several tens of kilohertz.
Microbubbles stay in water for a long time. The microbubbles disappear in a relatively short time, but at the same time, a large number of microbubbles are continuously generated from the microbubble generator, and therefore, the microbubbles are retained as a whole.
「インスリン様成長因子−１（ＩＧＦ−１）について」
[生体の恒常性維持における知覚神経の役割]
ヒトを含めて生物は、常に様々な環境の変化にさらされている。これらの環境の変化に対して、生物は、神経系、内分泌系、および免疫系の３つのシステムを巧妙に協調させて対応し、生体内部を一定の状態に維持している。生体内部の恒常性を保つ機能は、ホメオスターシスと呼ばれ、この機能が、正常に作動しているおかげで、我々は生命を維持できるのである。
生体に対する環境変化、例えば、「怪我をする」が起これば、これは、神経系や免疫系によって認識され、それぞれ、痛み、および細菌の侵入という情報として、中枢（脳）へ伝達される。中枢神経系は、全身の神経系および内分泌系を活性化させ、それぞれ、自律神経機能の活性化、およびステロイドなどのホルモン分泌亢進などの効果を惹起し、生体内の恒常性を維持しようとする。
この様に、知覚神経系は、レーダー網のように、全身に張り巡らされ、全身の状況の些細な変化をも感知し、環境の変化をいち早く中枢へ伝え、その後の環境の変化に対応するための重要な生体反応を惹起する上で、重要な役割を担っている。
About insulin-like growth factor-1 (IGF-1)
[Role of sensory nerve in maintaining homeostasis]
Living organisms including humans are constantly exposed to various environmental changes. Living organisms respond to these environmental changes by skillfully coordinating the three systems of the nervous system, endocrine system, and immune system, and maintain the inside of the living body in a constant state. The function of maintaining homeostasis inside the living body is called homeostasis, and thanks to the normal functioning of this function, we can maintain life.
When an environmental change to the living body, for example, “injuries” occurs, this is recognized by the nervous system and the immune system, and is transmitted to the center (brain) as information on pain and invasion of bacteria, respectively. The central nervous system activates the nervous system and endocrine system of the whole body, and activates autonomic nervous function and enhances the secretion of hormones such as steroids to maintain homeostasis in the living body. .
In this way, the sensory nervous system is stretched throughout the body like a radar network, senses even minor changes in the situation of the whole body, quickly transmits environmental changes to the center, and responds to subsequent environmental changes. It plays an important role in inducing important biological reactions.
[生体防御反応と臓器保護機構]
前述の様に、怪我をすると、免疫系では、細菌の侵入などを感知した白血球が活性化され、細菌の侵入から生体を守るための生体防御反応が展開される。細菌の侵入により、白血球の中でも、単球と呼ばれる細胞がまず活性化される。単球は、実際に細菌と戦う兵隊である好中球と呼ばれる細胞に戦いの指令を送る。この指令物質は、古くはガン細胞を殺す働きがあったことから、腫瘍壊死因子と呼ばれている。腫瘍壊死因子は、好中球を活性化し、好中球から、細菌を殺す武器である活性酸素種や蛋白分解酵素を放出させる。また、腫瘍壊死因子は、細菌などの攻撃で傷害された細胞を除去する働きをも持っている。傷害された細胞は、細胞死（アポトーシス）と呼ばれる機序によって除去される。
[Bioprotective response and organ protection mechanism]
As described above, when injured, the immune system activates leukocytes that sense the invasion of bacteria, and develops a biological defense reaction to protect the living body from the invasion of bacteria. Due to the invasion of bacteria, cells called monocytes are first activated among leukocytes. A monocyte sends a fight command to cells called neutrophils, which are soldiers that actually fight bacteria. This command substance was called tumor necrosis factor because it used to kill cancer cells. Tumor necrosis factor activates neutrophils and releases reactive oxygen species and proteolytic enzymes that are weapons that kill bacteria from neutrophils. Tumor necrosis factor also has a function of removing cells damaged by attacks such as bacteria. Damaged cells are removed by a mechanism called cell death (apoptosis).
知覚神経刺激による臓器保護機構生体に密に張り巡らされた知覚神経のネットワークは、生体の恒常性を攪乱する要因が作用すると、速やかにこれを察知する。
知覚神経表面には、カプサイシンなどのバニロイド化合物に対する受容体（バニロイド受容体.１）が存在する。この受容体は、４３℃の熱刺激、ｐＨ６以下の酸性環境、低濃度の腫瘍壊死因子やインターロイキン−１などの炎症性サイトカイン、プロスタグランジン、内因性マリファナであるアナンダマイド、ブラジキニン、トロンボキサンＡ２、およびロイコトリエンなどで活性化される。
すなわち、生体の恒常性をかく乱する要因が作用して、それに対する生体側の反応により生成されるこのような物質により、知覚神経が刺激されるのである。知覚神経が刺激されると、温痛覚が伝達され、生体は熱さや痛みを感じるが、同時に知覚神経末端からカルシトニン遺伝子関連ペプチド（CGRP）という知覚神経で産生されるペプチドを放出する。
CGRPは、血管内皮細胞を活性化し、腫瘍壊死因子の産生を抑制する作用を有する一酸化窒素やプロスタグランジンの産生を促進する。さらに、CGRPは、血管内皮細胞や臓器実質細胞の生存に重要な役割を担うインスリン様成長因子−１の産生も促進する。
Organ Protection Mechanism by Sensory Nerve Stimulation The sensory nerve network, which is tightly stretched around the living body, quickly detects when a factor that disturbs the homeostasis of the body acts.
A receptor for vanilloid compounds such as capsaicin (vanilloid receptor.1) exists on the sensory nerve surface. This receptor is heat-stimulated at 43 ° C., acidic environment at pH 6 or lower, low concentrations of inflammatory cytokines such as tumor necrosis factor and interleukin-1, prostaglandins, endogenous marijuana anandamide, bradykinin, thromboxane It is activated with A2, leukotriene and the like.
That is, the factor which disturbs the homeostasis of a living body acts, and the sensory nerve is stimulated by such a substance generated by the reaction on the living body side. When the sensory nerve is stimulated, a thermal pain sensation is transmitted, and the living body feels heat and pain, but simultaneously releases a peptide produced by the sensory nerve called calcitonin gene-related peptide (CGRP) from the terminal of the sensory nerve.
CGRP promotes the production of nitric oxide and prostaglandins that activate vascular endothelial cells and suppress the production of tumor necrosis factor. Furthermore, CGRP also promotes the production of insulin-like growth factor-1, which plays an important role in the survival of vascular endothelial cells and organ parenchymal cells.
インスリン様成長因子−１（ＩＧＦ−１）：
疾病予防とアンチエイジングに関わる重要な物質インスリン様成長因子−１は、分子量7500ペプチドで、細胞のアポトーシスを抑制し、細胞の生存、増殖、そして分化に不可欠な重要な物質である。
インスリン様成長因子−１は、成長ホルモンの末梢での作用発現物質で、筋肉細胞、神経細胞などの細胞の増殖分化に重要な役割を演じる。成長ホルモン欠損症で認められる多くの症候は、インスリン様成長因子−１の産生低下に起因すると考えられ、この病態の観察と成長ホルモン補充による効果の観察から、インスリン様成長因子−１の多彩で重要な作用が判明した。
インスリン様成長因子−１は、血糖を調節するインスリンと類似したシグナルを細胞に伝達し、血糖を低下させ、糖尿病の軽減に重要であるが、その他にも、蛋白質分解抑制（蛋白同化作用）、血圧低下、心機能の改善、高脂血症の改善、認知機能の上昇、抗うつ作用、アルツハイマー病予防、美肌効果、育毛作用、創傷治癒の促進、抗炎症作用、ナチュラルキラー細胞の活性化による免疫機能活性化作用などの作用が知られている。
また、成長ホルモンのアンチエイジング作用は、インスリン様成長因子−１の作用によるものである。インスリン様成長因子−１は、生体防御反応において、過剰に産生された腫瘍壊死因子によるアポトーシスを抑制するほか、アポトーシスによる細胞欠落を、新たに若い無傷な細胞を分裂増殖させることで、補充する作用を有する。
Insulin-like growth factor-1 (IGF-1):
Important Substance Involved in Disease Prevention and Anti-Aging Insulin-like growth factor-1 is a 7500 peptide having a molecular weight of 7500 and is an important substance essential for cell survival, proliferation and differentiation by suppressing cell apoptosis.
Insulin-like growth factor-1 is a substance that exhibits the action of growth hormone in the periphery, and plays an important role in the proliferation and differentiation of cells such as muscle cells and nerve cells. Many symptoms observed in growth hormone deficiency are thought to be due to decreased production of insulin-like growth factor-1. From the observation of this condition and the effect of growth hormone supplementation, various symptoms of insulin-like growth factor-1 were observed. An important effect was found.
Insulin-like growth factor-1 transmits a signal similar to insulin that regulates blood sugar to cells, lowers blood sugar, and is important for alleviating diabetes, but also inhibits protein degradation (anabolic action), Reduced blood pressure, improved cardiac function, improved hyperlipidemia, increased cognitive function, antidepressant action, Alzheimer's disease prevention, skin beautifying effect, hair growth action, promotion of wound healing, anti-inflammatory action, activation of natural killer cells Actions such as an immune function activation action are known.
The anti-aging action of growth hormone is due to the action of insulin-like growth factor-1. Insulin-like growth factor-1 suppresses apoptosis caused by excessively produced tumor necrosis factor in a host defense reaction, and supplements cell loss due to apoptosis by newly proliferating young intact cells. Have
本発明に係る実施形態を図１に基づいて説明する。
図１は、マウスを４０℃の水道水と４０℃の本願発明のマイクロバブル水に５分間浸漬した際及びマウスに何も処理をしない際（コントロール）の各種臓器、皮膚、血漿におけるインスリン様成長因子−１（ＩＧＦ−１）生成率（コントロール（１００）に対する比率）を示すものである。
なお、図において「コントロール」は、何もしない、そのままのマウスである。
「４０℃水道水」は、４０℃の温水にマウスを５分間入れて入浴させた場合であり、
「４０℃水道水＋マイクロバブル」は、４０℃の温水にマイクロバブルを発生させながら、マウスを５分間入浴させた場合である。
すなわち、マウスを４０℃の水道水と４０℃の本願発明のマイクロバブル水に５分間浸漬してから、マウスの各種臓器、皮膚、血漿におけるインスリン様成長因子−１（ＩＧＦ−１）生成率を測定した。
そして、その結果を図１に示した（ただし、コントロール（１００）に対する比率を示す）。
その結果から、マウスを４０℃の水道水に浸漬しただけでも体内のインスリン様成長因子−１濃度は上昇するが、４０℃の本願発明のマイクロバブル水に浸漬すると、一層体内のインスリン様成長因子−１濃度は上昇することが明確に解る。
特に肝臓及び血漿（血液）中のインスリン様成長因子−１濃度は飛躍的に上昇することが解った。
以上のことから、本願発明のマイクロバブル又はマイクロバブル水の供与により、生物体内のインスリン様成長因子−１濃度が上昇するため、生物の育生促進や、医療分野において多くの疾患への治療効果が期待できる。
すなわち、生体が急性の過大な、又は慢性の持続するストレスにより、それぞれ、重症感染症や生活習慣病を発症した場合、または、老化が促進されるような場合、マイクロバブルは、インスリン様成長因子−１産生を促進し、若い細胞を分裂させ、臓器の障害、炎症、又は老化の促進を抑制することが期待される。
An embodiment according to the present invention will be described with reference to FIG.
FIG. 1 shows insulin-like growth in various organs, skin, and plasma when a mouse is immersed in 40 ° C. tap water and 40 ° C. microbubble water of the present invention for 5 minutes and when no treatment is performed on the mouse (control). It shows the factor-1 (IGF-1) production rate (ratio to control (100)).
In the figure, “control” is a mouse that does nothing and does nothing.
“40 ° C. tap water” is a case where a mouse is placed in 40 ° C. warm water for 5 minutes to bathe,
“40 ° C. tap water + microbubble” is when the mouse is bathed for 5 minutes while generating microbubbles in warm water at 40 ° C.
That is, after immersing the mouse in 40 ° C tap water and 40 ° C microbubble water of the present invention for 5 minutes, the rate of insulin-like growth factor-1 (IGF-1) production in various organs, skin, and plasma of the mouse was determined. It was measured.
The results are shown in FIG. 1 (however, the ratio to the control (100) is shown).
As a result, the concentration of insulin-like growth factor-1 in the body rises only by immersing the mouse in tap water at 40 ° C., but when immersed in the microbubble water of the present invention at 40 ° C., the insulin-like growth factor in the body is further increased. It can be clearly seen that the -1 concentration increases.
In particular, it has been found that the concentration of insulin-like growth factor-1 in the liver and plasma (blood) increases dramatically.
From the above, since the concentration of insulin-like growth factor-1 in the organism increases due to the provision of microbubbles or microbubble water of the present invention, the growth of organisms is promoted and therapeutic effects on many diseases in the medical field are achieved. I can expect.
That is, when a living body develops severe infection or lifestyle-related disease due to acute excessive or chronic sustained stress, or when aging is promoted, microbubbles are insulin-like growth factors. -1 production, division of young cells, and suppression of organ damage, inflammation, or aging promotion are expected.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006223710A JP4968511B2 (en) | 2006-08-19 | 2006-08-19 | Method for producing insulin-like growth factor-1 (IGF-1) in vivo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006223710A JP4968511B2 (en) | 2006-08-19 | 2006-08-19 | Method for producing insulin-like growth factor-1 (IGF-1) in vivo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008043906A JP2008043906A (en) | 2008-02-28 |
| JP4968511B2 true JP4968511B2 (en) | 2012-07-04 |
Family
ID=39178150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006223710A Active JP4968511B2 (en) | 2006-08-19 | 2006-08-19 | Method for producing insulin-like growth factor-1 (IGF-1) in vivo |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4968511B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008156320A (en) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | Antioxidative functional water |
| JP2011115326A (en) * | 2009-12-02 | 2011-06-16 | Nanoplanet Kenkyusho:Kk | Method for annihilating escherichia coli or virus, or inhibiting proliferation thereof |
| WO2013006169A1 (en) * | 2011-07-06 | 2013-01-10 | Empire Technology Development Llc | Air purifier |
| CN103880146A (en) * | 2012-12-21 | 2014-06-25 | 陈晓波 | Plasma water purification device for fish tank needing no water changing |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3318304B2 (en) * | 1999-07-30 | 2002-08-26 | 野村電子工業株式会社 | Gas-liquid mixing device |
| JP2002143885A (en) * | 2000-11-14 | 2002-05-21 | Hirobumi Onari | Micro bubble |
| JP3829170B2 (en) * | 2001-05-01 | 2006-10-04 | 有限会社情報科学研究所 | Gas dissolved liquid medium production system |
| US8349192B2 (en) * | 2003-09-30 | 2013-01-08 | Reo Laboratory Co., Ltd. | Method for collapsing microbubbles |
| JP4080440B2 (en) * | 2004-03-05 | 2008-04-23 | 独立行政法人産業技術総合研究所 | Oxygen nanobubble water and method for producing the same |
| WO2006019107A1 (en) * | 2004-08-18 | 2006-02-23 | Fuki Co., Ltd. | Method of generating micro air bubble in liquid and air bubble generating apparatus |
| DE602004009930T2 (en) * | 2004-09-27 | 2008-02-28 | Nestec S.A. | Mixing device, coffee machine with such mixing device and application of such mixing device |
-
2006
- 2006-08-19 JP JP2006223710A patent/JP4968511B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008043906A (en) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farina Jr et al. | Curbing inflammation in burn patients | |
| JP4968511B2 (en) | Method for producing insulin-like growth factor-1 (IGF-1) in vivo | |
| US20040059388A1 (en) | Electrochemical treatment of tissues, especially tumors | |
| EA029314B1 (en) | Application of high-shear deformation in medicinal therapy | |
| Nizamutdinov et al. | Transcranial near-infrared light in treatment of neurodegenerative diseases | |
| Jani et al. | Ozone therapy: the alternative medicine of future | |
| Zhou et al. | Combination therapy based on targeted nano drug co-delivery systems for liver fibrosis treatment: A review | |
| WO2008049058A3 (en) | Cln2 treatment of alzheimer's disease | |
| Li et al. | Biomaterial-based therapeutic strategies for obesity and its comorbidities | |
| TWI580440B (en) | The Application of Surface to Cosmetics | |
| Salim et al. | Smart biomaterials for enhancing cancer therapy by overcoming tumor hypoxia: a review | |
| KR101970677B1 (en) | Health care room having spray nozzle of salt water | |
| JP2014515665A (en) | Method for producing a substance with a supersaturated gas, transdermal delivery device and use thereof | |
| EP3015108A1 (en) | Carbonated water-containing external preparation for promoting blood circulation, blood circulation-promoting device for same, and blood circulation-promoting method using same | |
| Eldershaw et al. | Resiniferatoxin and piperine: capsaicin-like stimulators of oxygen uptake in the perfused rat hindlimb | |
| US8888736B2 (en) | High shear application in medical therapy | |
| US20030113315A1 (en) | Squalane containing ultra fine particles of burning residue of carbon and method for producing the same | |
| JP2014515666A (en) | Method for producing a substance with a supersaturated gas, transdermal delivery device and use thereof | |
| KR100950220B1 (en) | Apparatus for producing functional washing water using micro bubble | |
| Hayashi et al. | Transient prevention of ethanol-induced gastric lesion by capsaicin due to release of endogenous calcitonin gene-related peptide in rats | |
| Al-Harrasi et al. | Olfactory Aromatherapy vs COVID-19: A Systematic Review | |
| WO2016066068A1 (en) | Use of metallothionein composite formulation as medication for treating cerebral stroke sequelae by acupoint entry | |
| RU2676836C2 (en) | Device for treatment of immune function deficiency and regulation of metabolism | |
| CN1290488C (en) | Micro bubble reagent in use for method of blood vessel embolism induced by ultrasonic and method of beauty culture of subtracting fat | |
| KR100952611B1 (en) | Apparatus for producing functional washing water using micro bubble |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090619 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120308 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120321 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4968511 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R255 | Notification that request for automated payment was rejected |
Free format text: JAPANESE INTERMEDIATE CODE: R2525 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R255 | Notification that request for automated payment was rejected |
Free format text: JAPANESE INTERMEDIATE CODE: R2525 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |